158 results about "Pancreatitides" patented technology

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide (PYY) (3-36), analogs thereof and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

The invention relates to a Chinese medicinal composition for treating acute pancreatitis. The Chinese medicinal composition is prepared from the following active pharmaceutical ingredients in parts by weight: 1 to 200 parts of red paeony root and 1 to 60 parts of raw rhubarb. The invention further provides an application of the Chinese medicinal composition. A traditional Chinese medicine compound preparation of the invention has the advantages that raw materials are commonly used traditional Chinese medicines to result in low price, the preparation is simple and the use is convenient, and has a remarkable curative effect for the acute pancreatitis by matching with the conventional western medicine therapy after years of clinical applications and pharmacological researches. In view of increase of incidence of the acute pancreatitis year by year, the traditional Chinese medicine compound preparation of the invention has the characteristics of no toxicity and capacity of being taken for a long term, thereby having wider market prospects.

If smooth transportation of bile toward the duodenum is difficult due to cancerous cells growing in the bile duct or due to stricture of the bile duct, a cylindrical stent may be implanted into the stenosed site of the bile duct to enable smooth supply of bile. Conventional stents have no risk of slippage at an implanted position thereof, but suffer from invasively growing cancerous cells. Although a covered stent having a coating has been proposed to solve invasion of the growing cancerous cells, the covered stent may have a risk of slippage at an implanted position thereof and also, may cause pancreatitis and cholelithiasis. To solve the above described problems, disclosed herein is a stent to prevent backflow of food from the duodenum to the bile duct while assuring smooth transportation of bile without a risk of unwanted displacement caused by the transported bile. The stent includes a cylindrical outer stent, and a downwardly tapered inner stent covered with a polytetrafluoroethylene (PTFE) or silicone coating having biocompatibility. The inner and outer stents are coupled to each other to define a double structure.

The present invention provides one kind of amylopsin activity detecting solution and its use. The present invention makes it possible to realize the routine monitoring of pancreas function and the clinical detection of acute pancreatitis.

The invention discloses a severe pancreatitis prediction model construction method based on a machine learning method, and the method comprises the following steps: obtaining clinical and laboratory index related data of a prediction object, and carrying out the preprocessing of the obtained data; removing missing or slightly-changed indexes; carrying out data binning; screening a severe pancreatitis data prediction model; pre-training the selected model; screening and determining characteristic indexes associated with 10 severe pancreatitis according to a pre-training result, and training again; according to the working characteristic curve of the subject, a threshold value suitable for a prediction algorithm is determined, and then a final severe pancreatitis data prediction model is obtained. The non-invasive severe pancreatitis diagnosis model based on multiple clinical indexes solves the problem of diagnosis lag, is high in prediction speed and high in accuracy, and can provide reference for clinical diagnosis of severe pancreatitis.

The invention discloses a Chinese herbal medicine for treating acute pancreatitis. The Chinese herbal medicine is prepared from the following medicines in parts by weight: 25-35 parts of radix bupleuri, 25-35 parts of bitter orange, 15-25 parts of radix paeoniae rubra, 25-35 parts of rhizoma cyperi, 25-35 parts of the rhizome of chuanxiong, 25-35 parts of radix curcumae, 25-35 parts of rhizoma corydalis, 25-35 parts of salvia, 15-25 parts of dandelion, 15-25 parts of herba scutellariae barbatae, 35-45 parts of amur ampelopsis stem, 15-25 parts of coptis root, 15-25 parts of herba patriniae and 25-35 parts of sticktight. The Chinese herbal medicine is prepared by adding 1600 parts by weight of water, after the water is boiled, decocting the medicines with slow fire for 20-30 minutes, filtering the decoction and collecting the supernatant, decocting the supernatant three times, bottling and uniformly mixing the supernatant decocted three times and then sterilizing the supernatant under a high temperature for later use. Radix bupleuri is taken as the monarch, bitter orange and radix paeoniae rubra are taken as the ministers, rhizoma cyperi, the rhizome of chuanxiong, radix curcumae and rhizoma corydalis are taken as the assistants, and salvia, dandelion, herba scutellariae barbatae, amur ampelopsis stem, coptis root, herba patriniae and sticktight are taken as the guides.

The invention provides acute pancreatitis prognostic markers, an acute pancreatitis prognostic prediction model and application of the prediction model. The markers comprise any one or a combination of at least two of hsa-miR-4265, hsa-miR-1208, hsa-miR-516a or hsa-miR-3127. The hsa-miR-4265, the hsa-miR-1208, the hsa-miR-516a and the hsa-miR-3127 disclosed by the invention have obvious correlation with the acute pancreatitis with the continuous organ failure. According to the relative expression quantity of the markers, the acute pancreatitis prognosis prediction model can be constructed, whether a patient suffering from acute pancreatitis suffers from continuous organ failure or not is predicted in an individualized mode, and accurate and useful prognosis information is provided for thepatient suffering from acute pancreatitis.

The invention is in the field of biotechnology. Specifically it describes the application and pharmaceutical composition of Reg4. The invention describes the applications of the protein as following in (a) or (b) in preparing drugs for treating acute pancreatitis: (a) the protein whose amino acid sequence is shown as SEQ ID NO. 1, or bioactive fragments, or analogs; (b) the proteins whose amino acid sequence have at least 70% homology comparing with amino acid sequence described in (a) and have activity for treating acute pancreatitis. The protein described in this invention treats acute pancreatitis effectively and may provide new therapy for treating acute pancreatitis clinically.